A guide to finding out your breast cancer risk, and whether you should be tested for BRCA mutations. I like my boobs. They’re great. They look fine in a T-shirt, it feels good when they're touched, ...

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

A clinician-led approach boosts genetic testing among relatives of people with newly detected pathogenic variants — and could help close a gap in hereditary cancer prevention.

Genetics is always changing. It seems as if every day there is a new article about a new study, and trying to navigate all of this information can be quite confusing. This past month, a new study was ...

Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...

Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. Background: A BRCA1 gene mutation is well-known risk factor for breast ...

In May 2013, nearly 20 years after the discovery that mutations on the BRCA1 and BRCA2 genes could lead to a higher risk of breast and ovarian cancer, A-list Hollywood actress Angelina Jolie garnered ...

Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...

Sep 21, 2020 South San Francisco / CA / USA - Myriad headquarters in Silicon Valley; Myriad Genetics, Inc. is an American molecular diagnostic company UNITED STATES - APRIL 15, 2013: Lisa Schlager ...

Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use ...